A Phase I Single Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ZSP1273
Latest Information Update: 03 Dec 2023
Price :
$35 *
At a glance
- Drugs Onradivir (Primary)
- Indications Influenza A virus infections
- Focus Pharmacokinetics
- Sponsors Guangdong Raynovent Biotech
- 17 Jul 2023 Status changed from active, no longer recruiting to completed.
- 15 Jun 2023 Status changed from not yet recruiting to active, no longer recruiting.
- 16 May 2023 New trial record